Forward Looking Statements

Some of the information presented here today may contain projections or other forward-looking statements regarding future events or the future financial performance of the Company. These statements are based on management’s current expectations and the actual events or results may differ materially and adversely from these expectations. We refer you to the documents the Company files from time to time with the Securities and Exchange Commission, specifically, the Company’s annual reports on Form 10-K, its quarterly reports on Form 10-Q, and its current reports on Form 8-K. These documents identify important risk factors that could cause the actual results to differ materially from those contained in the Company’s projections or forward-looking statements.
Our vision...

A trusted advisor transforming patients’ lives worldwide with pioneering molecular diagnostics

The global leader in personalized medicine
Myriad’s 4 in 6 Strategy

Answering patients’ **four** most pressing questions

Will I get a disease?
Do I have a disease?
Should I treat this disease?
How should I treat this disease?

**In six medical specialties**

- Oncology
- Preventive Care
- Urology
- Dermatology
- Autoimmune
- Neuroscience
Diagnostics Are the Keystone for Personalized Medicine
Focused on Six Medical Specialties with Over $200B in Waste

Oncology  Preventive Care  Urology  Dermatology  Autoimmune  Neuroscience

≈$700B in U.S. Healthcare Spending

30% Healthcare Spending Waste*

Diagnostics represent 3% of spend but drive 70% of healthcare decision making**

*Eliminating Waste in U.S. Healthcare
**Clinical Lab Products Magazine – “The Value of Diagnostics”
Myriad Leads Personalized Medicine Industry
Unique Scale and Expertise Creates Sustainable Competitive Advantage

1. only profitable R&D driven personalized medicine company

2.5 million tests performed; unmatched reputation for quality

2,500 employees dedicated to the Myriad mission

>1,000 scientific publications to date; extensive research capabilities

3. expertise with all three types of biomarkers (DNA, RNA, and proteins)

1. only personalized medicine company with broad regulatory experience

>90,000 ordering physicians since inception; deep relationships

95% of payers with Myriad is an in-network provider
Our Strategic Goals

- **Revenue Growth CAGR**: >10%
- **Operating Margin**: >30%
- **Products with Revenue >$50 Million**: 7
- **International Revenue**: >10%
Continued Leadership in an Expanding Hereditary Cancer Market

Diversify Revenue With New Products

Grow Kit Products in Major International Geographies
Strategic Imperatives to Achieve Our Goals

Continued Leadership in an Expanding Hereditary Cancer Market

Diversify Revenue With New Products

Grow Kit Products in Major International Geographies
Quality Hereditary Cancer Testing Saves Lives
Can Reduce Cancer Risks by >90%

- Deleterious mutations lead to up to a 7-fold risk of breast cancer and up to a 16-fold risk of colorectal cancer.
- ≈15M adults in United States qualify for hereditary cancer testing; less than 10% have been tested.
- Cost effective interventional steps can reduce lifetime risk to below the general population risk.

National Cancer Institute; Surgery to Reduce Risk of Breast Cancer
Risk of colorectal adenoma and carcinoma after colectomy for colorectal cancer in patients meeting Amsterdam criteria.
Hereditary Cancer Business Has Been Durable
Significant Competitive Advantages Results in Continued Leadership

- In network with 95% of commercial payers; 65% under long-term, fixed-price contracts

*Based on analyst consensus estimates
A Market that Demands Perfection
Three Competitive Advantages Provide Important Differentiation

Lab accuracy:
• 85,000 base pairs with 100% accuracy
• 856 steps using 23 major technology platforms
• 100 proprietary software applications

Variant classification:
• 20 years of research; > $100M investment
• >2.5M patients tested; 50k variants identified
• 5 proprietary methods with 99.5% validity

Customer service & support:
• Over 40k ordering physicians annually
• 450 field educators
• Extensive reimbursement support
• Lifetime commitment to patients
Substantial Opportunity for Volume Growth
New Indications Can Double Market Potential for Hereditary Cancer

- Broaden eligibility criteria
  - Pancreatic
  - Colon
  - Breast <65
  - Prostate

- Expand testing beyond breast cancer patients
- Increase penetration in unaffected population
Pricing and Cost Bands for Hereditary Cancer Panels
Myriad Quality Justifies Significant Price Premium

*Association for Molecular Pathology micro-costing analysis
Strategic Imperatives to Achieve Our Goals

- Continued leadership in an Expanding Hereditary Cancer Market
- Diversify Revenue With New Products
- Grow Kit Products in Major International Geographies
## Industry Leading Pipeline
Sold Through Multiple Channels Generating Commercial Leverage

<table>
<thead>
<tr>
<th>TAM</th>
<th>Stage 1</th>
<th>Stage 2</th>
<th>Stage 3</th>
<th>Stage 4</th>
</tr>
</thead>
<tbody>
<tr>
<td>myRisk Hereditary Cancer*</td>
<td>$5B</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GeneSight*</td>
<td>$4B</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vectra DA*</td>
<td>$3B</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prolaris*</td>
<td>$1.5B</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EndoPredict*</td>
<td>$0.7B</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>myChoice HRD</td>
<td>$6B</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>myPath Melanoma</td>
<td>$0.8B</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>myPlan Lung Cancer</td>
<td>$0.2B</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>myPlan Renal Cancer</td>
<td>$0.4B</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>myPath Bipolar</td>
<td>$5B</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>myPath Endometriosis</td>
<td>$3B</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>myPath Psoriatic Arthritis</td>
<td>$3B</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* Revenue Generation

- **Oncology**
- **Preventive Care**
- **Urology**
- **Autoimmune**
- **Dermatology**
- **Neuroscience**

## Value Proposition for Pipeline Products

**Total Addressable Market >$25B Opportunity**

<table>
<thead>
<tr>
<th>Product</th>
<th>Indication</th>
<th>Utility</th>
<th>Global TAM</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>myRisk</strong></td>
<td>Personal or family history of cancer</td>
<td>Reduces cancer risk by 90%</td>
<td>$5 billion</td>
</tr>
<tr>
<td><strong>genesight</strong></td>
<td>Treatment resistant depression</td>
<td>Improves response to psychotropic drugs</td>
<td>$4 billion</td>
</tr>
<tr>
<td><strong>VectraDA</strong></td>
<td>Rheumatoid arthritis (RA)</td>
<td>Predicts disease progression to optimize drug treatment</td>
<td>$3 billion</td>
</tr>
<tr>
<td><strong>Prolaris</strong></td>
<td>Prostate cancer</td>
<td>Identifies patients that can pursue active surveillance</td>
<td>$1.5 billion</td>
</tr>
<tr>
<td><strong>EndoPredict</strong></td>
<td>ER+ breast cancer</td>
<td>Identifies patients that can forgo chemotherapy</td>
<td>$0.7 billion</td>
</tr>
<tr>
<td><strong>myChoiceHRD</strong></td>
<td>Cancers caused by DNA repair defects</td>
<td>Predicts responders to DNA damaging agents</td>
<td>$6 billion</td>
</tr>
<tr>
<td><strong>myPath</strong></td>
<td>Suspicious skin lesions</td>
<td>Differentiates melanoma from benign lesions with &gt;90% accuracy</td>
<td>$0.8 billion</td>
</tr>
<tr>
<td><strong>myPlan</strong></td>
<td>Early stage lung cancer</td>
<td>Identifies patients that can benefit from chemotherapy</td>
<td>$0.2 billion</td>
</tr>
</tbody>
</table>
Substantial Diversification in Testing Volumes
≈ Two-Thirds of Volume Generated by New Products

FY13
≈180,000 tests
99% Hereditary Cancer

FY17E
35% CAGR
≈600,000 tests
≈ 33% Hereditary Cancer

Hereditary Cancer
Prolaris
Vectra DA
GeneSight
EndoPredict
Additional Reimbursement is a Growth Multiplier
Potential to Triple Average Selling Price (ASP)

<table>
<thead>
<tr>
<th>Product</th>
<th>Current ASP</th>
<th>Target ASP</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prolaris</td>
<td>$50M</td>
<td></td>
</tr>
<tr>
<td>Vectra DA</td>
<td>$100M</td>
<td></td>
</tr>
<tr>
<td>GeneSight</td>
<td>$400M</td>
<td></td>
</tr>
<tr>
<td>EndoPredict</td>
<td>$20M</td>
<td></td>
</tr>
<tr>
<td>Combined</td>
<td>$570M</td>
<td></td>
</tr>
</tbody>
</table>

Current Revenue Run Rate at Full Reimbursement

Myriad Portfolio Offers Unprecedented Payer Economics
Large Payer Can Save >$200M per year

<table>
<thead>
<tr>
<th>Product</th>
<th>Indication</th>
<th>Value Driver</th>
<th>2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>EndoPredict</td>
<td>Breast cancer recurrence testing</td>
<td>Avoid unnecessary chemotherapy and reduce unit cost of testing.</td>
<td>$0.11 PMPM</td>
</tr>
<tr>
<td>VectraDA</td>
<td>Rheumatoid arthritis biomarker</td>
<td>Require biomarker results before biologic use in methotrexate non-responders.</td>
<td>$0.20 PMPM</td>
</tr>
<tr>
<td>GeneSight</td>
<td>Pharmacogenomic testing for depression &amp; anxiety</td>
<td>More efficient spending on psychotropic drugs and lower healthcare utilization.</td>
<td>$0.06 PMPM</td>
</tr>
<tr>
<td>Prolaris</td>
<td>Prostate cancer testing</td>
<td>Require test results in NCCN® low- and favorable intermediate-risk Prostate Cancer; appropriately reduce surgical and radiation therapies.</td>
<td>$0.19 PMPM</td>
</tr>
</tbody>
</table>

Est. Gross Savings (including test costs) $0.51 PMPM

Myriad can save a large payer >$200M per year
Companion Diagnostics Represent Near-Term Opportunity >$1B
10 Pivotal Clinical Studies Report in Next 18 Months

<table>
<thead>
<tr>
<th>Indication</th>
<th>Number of Studies</th>
<th>First Data Expected</th>
<th>Total Patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>HER2- metastatic breast cancer</td>
<td>4</td>
<td>Mar. 2017</td>
<td>160,000</td>
</tr>
<tr>
<td>Neoadjuvant TNBC</td>
<td>2</td>
<td>Mar. 2017</td>
<td>70,000</td>
</tr>
<tr>
<td>Other ovarian</td>
<td>3</td>
<td>Mar. 2017</td>
<td>50,000</td>
</tr>
<tr>
<td>Pancreatic</td>
<td>1</td>
<td>Dec. 2017</td>
<td>100,000</td>
</tr>
</tbody>
</table>

Total: 380,000
Strategic Imperatives to Achieve Our Goals

- Continued leadership in an Expanding Hereditary Cancer Market
- Diversify Revenue With New Products
- Grow Kit Products in Major International Geographies
Total Available Market (TAM) in 10 Major International Markets > U.S.

- **EU5 + Canada Near Term Opportunity:** ≈40% of U.S. Market
- **Long-Term Opportunity:** > 70% of U.S. Market

- **40%**
- **17%**
- **29%**
International Growth Focused in Major Geographies
Kit Products Appeal to Existing Business Models

<table>
<thead>
<tr>
<th>COUNTRIES</th>
<th>KITS</th>
<th>REFERENCE TESTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Near-Term Growth:</td>
<td>EU5 + Canada</td>
<td>DNA (multiple platforms):</td>
</tr>
<tr>
<td></td>
<td>RNA (platform partner):</td>
<td>Companion Diagnostics</td>
</tr>
<tr>
<td></td>
<td>• EndoPredict</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Prolaris</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• myPlan Lung</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• myPath Melanoma</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• myPlan Renal</td>
<td></td>
</tr>
<tr>
<td>Long-Term Growth:</td>
<td>Japan, China, and Brazil</td>
<td>Protein (platform partner):</td>
</tr>
<tr>
<td></td>
<td>RNA (platform partner):</td>
<td>• Vectra DA</td>
</tr>
<tr>
<td></td>
<td>• EndoPredict</td>
<td>• myPath Bipolar</td>
</tr>
<tr>
<td></td>
<td>• Prolaris</td>
<td>• myPath Pancreatic</td>
</tr>
<tr>
<td></td>
<td>• myPlan Lung</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• myPath Melanoma</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• myPlan Renal</td>
<td></td>
</tr>
</tbody>
</table>
International Contribution Growing Rapidly
More Than 6x Increase Since Launch

Goal to have international product revenue comprise 10% of sales
Financial Outlook
Our Strategic Goals

- >10% Revenue Growth CAGR
- >30% Operating Margin
- 7 Products with Revenue >$50 Million
- International Revenue >10%
Historical Financial Performance
Strong Track Record of Revenue and Operating Income Growth

Historical Revenue

FY07 FY08 FY09 FY10 FY11 FY12 FY13 FY14 FY15 FY16
$0 $200 $400 $600 $800 $1000 $1200 $1400 $1600 $1800

20% CAGR

Historical Operating Income

FY07 FY08 FY09 FY10 FY11 FY12 FY13 FY14 FY15 FY16
$0 $100 $200 $300 $400 $500 $600 $700 $800 $900

21% CAGR

Celebrity publicity impact
One Path To Achieving 10% Revenue CAGR
Full Reimbursement and Modest Growth

Revenue (in mil.)

$0

$250

$500

$750

$1,000

$1,250

$1,500

$1,750

FY15

FY16

FY17E

Stage 3
Product 15%
CAGR

Stage 2
Products

Tolerable
Hereditary
Cancer Losses

FY20

10% CAGR

($300M)

Hereditary Cancer

Non-Hereditary Cancer

Non-Hereditary Cancer With 75% Reimbursement
Profitability Benefits From Significant Leverage
Additional Reimbursement + Volume Growth Through Existing Sales Channels

- FY16
- FY17E
- Stage 2 & 3 Product Growth
- Tolerable Hereditary Cancer Losses
- FY20

Adjusted Operating Margin

Operating Margin
Operating Margin With 75% Reimbursement

($225M) in HC Operating Profit
### Uses of Cash

<table>
<thead>
<tr>
<th>Uses of Cash</th>
<th>Current Focus</th>
<th>GOAL</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>R&amp;D</strong></td>
<td>9% of revenue</td>
<td>Invest in late stage reimbursement studies</td>
</tr>
</tbody>
</table>
| **M&A**              | Integration of Assurex and Sividon Acquisitions | • Pay $200M in milestones due next two years  
                        |                                                             | • Assess opportunities that fit 4in6 strategy with potential for near-term accretion |
| **Debt Repayment**   | $200M                                      | Reduce with excess free cash flow                                   |
| **Share Repurchase** | $174M authorized                           | Opportunistic open market purchases                                |
Worldwide Leader in Personalized Medicine

• We are entering the golden age for personalized medicine
• Molecular diagnostics are the keystone for improving patient outcomes while eliminating waste in healthcare spending
• Myriad is the pioneer of “research-based” and “education-centric” business model for molecular diagnostics
• We are the best positioned company to lead this revolution in healthcare